The Manufacturers Life Insurance Company Boosts Position in Dianthus Therapeutics, Inc. $DNTH

The Manufacturers Life Insurance Company raised its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 154.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 65,238 shares of the company’s stock after purchasing an additional 39,640 shares during the period. The Manufacturers Life Insurance Company’s holdings in Dianthus Therapeutics were worth $5,475,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. PNC Financial Services Group Inc. raised its stake in shares of Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares during the last quarter. First Horizon Corp acquired a new stake in Dianthus Therapeutics in the 1st quarter valued at about $32,000. Virtus Investment Advisers LLC increased its holdings in Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares in the last quarter. Royal Bank of Canada increased its holdings in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on DNTH. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, Truist Financial raised their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $124.27.

Insider Activity at Dianthus Therapeutics

In related news, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. The trade was a 86.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 87,779 shares of company stock valued at $7,985,235. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Trading Down 2.3%

NASDAQ:DNTH opened at $109.92 on Friday. The firm has a market cap of $6.01 billion, a price-to-earnings ratio of -26.49 and a beta of 1.22. The company’s 50-day moving average is $94.40 and its two-hundred day moving average is $80.45. Dianthus Therapeutics, Inc. has a 12-month low of $18.08 and a 12-month high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.